210 related articles for article (PubMed ID: 16911786)
1. Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.
Jacquet V; Morose W; Schwartzman K; Oxlade O; Barr G; Grimard F; Menzies D
BMC Public Health; 2006 Aug; 6():209. PubMed ID: 16911786
[TBL] [Abstract][Full Text] [Related]
2. Domestic returns from investment in the control of tuberculosis in other countries.
Schwartzman K; Oxlade O; Barr RG; Grimard F; Acosta I; Baez J; Ferreira E; Melgen RE; Morose W; Salgado AC; Jacquet V; Maloney S; Laserson K; Mendez AP; Menzies D
N Engl J Med; 2005 Sep; 353(10):1008-20. PubMed ID: 16148286
[TBL] [Abstract][Full Text] [Related]
3. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
Trials; 2020 May; 21(1):383. PubMed ID: 32370774
[TBL] [Abstract][Full Text] [Related]
4. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
Holland DP; Sanders GD; Hamilton CD; Stout JE
Am J Respir Crit Care Med; 2009 Jun; 179(11):1055-60. PubMed ID: 19299495
[TBL] [Abstract][Full Text] [Related]
5. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
Jasmer RM; Snyder DC; Chin DP; Hopewell PC; Cuthbert SS; Antonio Paz E; Daley CL
Am J Respir Crit Care Med; 2000 Nov; 162(5):1648-52. PubMed ID: 11069790
[TBL] [Abstract][Full Text] [Related]
6. Treatment of tuberculosis in Haiti.
Long R; Scalcini M; Ollé-Goig J
Am J Public Health; 2001 Oct; 91(10):1546-7. PubMed ID: 11574298
[No Abstract] [Full Text] [Related]
7. Efficacy of DOTS strategy in treatment of respiratory tuberculosis in Gorgan, Islamic Republic of Iran.
Abassi A; Mansourian AR
East Mediterr Health J; 2007; 13(3):664-9. PubMed ID: 17687840
[TBL] [Abstract][Full Text] [Related]
8. The comparison of tuberculosis treatments: a short course therapy and the directly observed short course treatment (DOTS), East Java Province, Indonesia.
Roosihermiatie B; Nishiyama M; Nakae K
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):85-8. PubMed ID: 11023071
[TBL] [Abstract][Full Text] [Related]
9. The long-term health and economic benefits of DOTS implementation in Ecuador.
Oxlade O; Vaca J; Romero E; Schwartzman K; Graham B; Hernandez L; Tannenbaum T; Menzies D
Can J Public Health; 2006; 97(1):14-9. PubMed ID: 16512320
[TBL] [Abstract][Full Text] [Related]
10. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis treatment: dangerous regimens?
Rieder HL; Arnadottir T; Trébucq A; Enarson DA
Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
[No Abstract] [Full Text] [Related]
13. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
Rose DN
Ann Intern Med; 1998 Nov; 129(10):779-86. PubMed ID: 9841583
[TBL] [Abstract][Full Text] [Related]
14. Four-month, four-drug preventive therapy for inactive pulmonary tuberculosis.
Goldberg SV; Duchin JS; Shields T; Nolan CM
Am J Respir Crit Care Med; 1999 Aug; 160(2):508-12. PubMed ID: 10430721
[TBL] [Abstract][Full Text] [Related]
15. Clinical response of newly diagnosed HIV seropositive & seronegative pulmonary tuberculosis patients with the RNTCP Short Course regimen in Pune, India.
Tripathy S; Anand A; Inamdar V; Manoj MM; Khillare KM; Datye AS; Iyer R; Kanoj DM; Thakar M; Kale V; Pereira M; Risbud AR
Indian J Med Res; 2011 May; 133(5):521-8. PubMed ID: 21623038
[TBL] [Abstract][Full Text] [Related]
16. [Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results)].
Pretet S; Grosset J; Perdrizet S
Bull Int Union Tuberc; 1978 Dec; 53(4):260-1. PubMed ID: 387140
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
[TBL] [Abstract][Full Text] [Related]
18. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
19. [Short-course chemotherapy of tuberculosis with pyrazinamide].
Asai S; Futsuki Y; Tomari S; Araki J
Nihon Rinsho; 1998 Dec; 56(12):3087-90. PubMed ID: 9883615
[TBL] [Abstract][Full Text] [Related]
20. Present status of chemotherapy for tuberculosis.
Grosset JH
Rev Infect Dis; 1989; 11 Suppl 2():S347-52. PubMed ID: 2652251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
